Scientific publications
Bone metastasis in differentiated thyroid cancer: Spanish multicenter study of clinical characteristics, survival and prognostic factors. Scientific Publication
Suset Dueñas-Disotuar 1 , Ana Piñar-Gutiérrez 1 , Irene de Lara-Rodríguez 1 , Julia Sastre-Marcos 2 , Emma Anda-Apiñániz 3 , Amelia Oleaga-Alday 4 , Juan Carlos Galofré-Ferrater 5 , Aida Orois-Añon 6 , Victoria Alcázar-Lázaro 7 , Laia Martínez-Guasch 8 , Cecilia Sánchez-Ragnarsson 9 , María Ángeles Gálvez-Moreno 10 , Cristina Familiar-Casado 11 , Tomás Martín-Hernández 12 , Ana R Romero-Lluch 1
Objective: This study describes the characteristics, survival and prognostic factors in a cohort of patients with bone metastases (BM) from differentiated thyroid carcinoma (DTC).
Methods: This was a multicenter retrospective observational study conducted in Spain, including patients diagnosed with DTC and BM between 1980 and 2022. A Cox regression analysis was performed to examine prognostic factors for survival. Kaplan-Meier and log-rank tests were performed for survival analysis and comparison between groups.
Results: A total of 133 patients were included with a median follow-up of 40 (17-70) months. Seventy patients (52.6%) had BM at the initial diagnosis. Fifty-two (39.1%) had follicular carcinoma. Sixty-six (49.6%) presented multiple BM. The most frequent location was the spine (63.2%). Other metastases were present at diagnosis in 88 (66.2%), mainly lung (60.9%). BM were treated with I131 in 91 (68.4%) patients, with BM uptake in 63 (47.4%). Fifty-six (42.1%) received treatment with multikinase inhibitors. Fifty-three (3.9%) had skeletal-related events. Seventy-two (54.1%) died. The 3-, 5- and 10-year survival was 53.5, 39.5% and 28.5%, respectively. Significant prognostic factors in the multivariate analysis were the presence of lymph node metastases (N1) HR 1.71 (95% CI 1.005-2.098; p=0.048), BM treatment with I131 HR 0.532 (95% CI 0.304-0.931; p=0.027) and age ≥67 years at BM diagnosis HR 1.991 (95% CI 1.142-3.47; p=0.015).
Conclusions: Survival of DTC patients with BM treated in a Spanish cohort was 39.5% at 5 years and 28.5% at 10 years. Patients with BM treated with I131 appear to have a better outcome in terms of mortality and the presence of lymph node involvement and age over 67 years were associated with higher mortality.
CITATION Front Endocrinol (Lausanne). 2024 Nov 7:15:1466245. doi: 10.3389/fendo.2024.1466245. eCollection 2024
Our authors
